NAFLD Listed on an Ultrasound
An imaging label should be followed by metabolic and fibrosis assessment.
- Share when the problem started
- Bring prior testing and treatment details
Get patient-focused guidance for NAFLD or MASLD findings, liver-test trends, fibrosis staging, metabolic risk, NASH/MASH assessment, and progression prevention. GastroDoxs helps you understand testing, treatment choices, warning signs, and the next step.
GastroDoxs GutRescue Mission™ helps patients move from uncertainty to a practical plan for NAFLD or MASLD findings, liver-test trends, fibrosis staging, metabolic risk, NASH/MASH assessment, and progression prevention.
Condition-specific evaluation, evidence-based choices, clear scope, and coordinated follow-up
The visit explains what NAFLD, MASLD, NASH, MASH, fibrosis, and cirrhosis mean for the individual patient.
FIB-4, platelet trends, elastography, and selected MRI help identify advanced scarring risk.
Patients with higher-risk disease may need specialist medication review in addition to metabolic treatment.
Diabetes, obesity, cholesterol, blood pressure, sleep apnea, and smoking affect long-term outcomes.
A clear path from scheduling and records review to a patient-specific care plan
Review why the term appeared on imaging or laboratory follow-up and whether another liver cause has been excluded.
Bring FIB-4 inputs, elastography, imaging, liver tests, diabetes and cholesterol results, and a medication list.
Your clinician evaluates whether inflammation or advanced fibrosis is likely and whether more testing or medication review is needed.
You receive clear timing for repeat laboratory testing, elastography, metabolic treatment, and advanced-liver surveillance.
Your guardians. GastroDoxs GutGuardians™ is our team of gastroenterologists board-certified by the American Board of Internal Medicine (ABIM) - a physician-led defense force of specialists, systems, and solution pathways working together to protect, detect, solve, and defend your digestive health through expert GI evaluation, advanced diagnostic screening, and endoscopic evaluation - commanded from your first concern to your last follow-up, and every critical stage in between.
Your rescue plan. When your diagnosis is confirmed, GastroDoxs GutRescue Mission™ deploys at full force - a gastroenterologist-led intervention plan delivering advanced colonoscopy, upper endoscopy, capsule endoscopy, and precision biologic and medication management across the full range of digestive conditions and complex GI emergencies - fighting for you with everything we have.
Book when symptoms, test results, current treatment, or the next step remains unclear
An imaging label should be followed by metabolic and fibrosis assessment.
ALT and AST can fluctuate and may be normal despite significant fibrosis.
Steatohepatitis cannot be diagnosed from symptoms alone.
Patients with diabetes, high FIB-4, elevated liver stiffness, or advanced fibrosis need a defined follow-up plan.
This guidance was medically reviewed to help patients understand NAFLD or MASLD findings, liver-test trends, fibrosis staging, metabolic risk, NASH/MASH assessment, and progression prevention. Recommendations depend on the complete history, examination, test results, treatment response, and clinical urgency.
GastroDoxs offers NAFLD and MASLD evaluation across Houston-area offices for patients who need fibrosis staging, metabolic-risk review, NASH/MASH treatment decisions, or liver monitoring.
Schedule evaluation after NAFLD/MASLD is found on imaging, liver enzymes remain abnormal, FIB-4 is indeterminate or high, metabolic risks are present, or the fibrosis stage and follow-up plan are unclear.
A gastroenterologist or hepatologist reviews imaging, alcohol exposure, medicines, metabolic risks, laboratory trends, and other liver causes. The diagnosis is usually clinical, while fibrosis risk is assessed separately.
Ultrasound may show liver fat and exclude some structural problems, but it cannot reliably stage fibrosis or prove steatohepatitis. The next step may include FIB-4, elastography, MRI, or additional laboratory testing.
Transient elastography, often called FibroScan, estimates liver stiffness and may estimate liver fat. It helps stratify fibrosis risk, but results must be interpreted with blood tests, body size, inflammation, and the full clinical picture.
Bring laboratory trends, imaging reports, elastography results, medicine and supplement lists, alcohol history, diabetes and cholesterol results, prior liver evaluations, and any family history of liver disease.
Yes. Weight, glucose, cholesterol, blood pressure, sleep, nutrition, and activity are central to metabolic liver care. Treatment should protect muscle and cardiovascular health while reducing liver risk.
Yes. Persistent ALT or AST elevation should be interpreted with platelets, bilirubin, albumin, metabolic risks, alcohol and medicine exposure, viral hepatitis testing, and fibrosis assessment. Normal enzymes do not rule out advanced fibrosis.
A specialist visit for NAFLD/MASLD should clarify the diagnosis, fibrosis risk, metabolic drivers, treatment priorities, and the timing of repeat testing.
Prompt evaluation is needed for jaundice, abdominal or leg swelling, confusion, vomiting blood, black stools, severe weakness, low platelets, or rapidly worsening liver tests. Severe symptoms require emergency care.
Yes. FIB-4, platelets, elastography, MR elastography, imaging, and selected liver biopsy can assess fibrosis and possible steatohepatitis. The result guides treatment intensity and surveillance.
A specialist visit for NAFLD/MASLD should clarify the diagnosis, fibrosis risk, metabolic drivers, treatment priorities, and the timing of repeat testing.
Yes. Weight, glucose, cholesterol, blood pressure, sleep, nutrition, and activity are central to metabolic liver care. Treatment should protect muscle and cardiovascular health while reducing liver risk.
After risk review, the plan may include metabolic treatment, repeat laboratory testing, elastography, medication eligibility review, nutrition support, or cirrhosis surveillance. Higher-risk findings may require hepatology follow-up.
Follow-up depends on fibrosis risk and treatment response. Lower-risk patients may be reassessed periodically, while diabetes, high FIB-4, elevated liver stiffness, advanced fibrosis, or cirrhosis requires closer monitoring.
Treatment can reduce progression risk by improving weight, diabetes, cholesterol, blood pressure, sleep apnea, activity, and alcohol exposure. Selected higher-risk patients may also qualify for specialist-directed medication treatment.
Schedule GastroDoxs care for NAFLD or MASLD findings, liver-test trends, fibrosis staging, metabolic risk, NASH/MASH assessment, and progression prevention. Bring prior records and a medication list so your clinician can explain the safest next step. Seek emergency care for confusion, vomiting blood, black stools, fainting, severe swelling, fever with advanced liver disease, or rapidly worsening jaundice.